{"doi":"10.1016/j.clml.2020.11.025","title":"The Emerging Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient Outcomes","abstract":null,"journal":"Clinical Lymphoma Myeloma and Leukemia","year":2021,"id":639690,"datarank":1.5391245593043505,"base_score":3.332204510175204,"endowment":3.332204510175204,"self_citation_contribution":0.49983067652628066,"citation_network_contribution":1.0392938827780698,"self_endowment_contribution":0.49983067652628066,"citer_contribution":1.0392938827780698,"corpus_percentile":null,"corpus_rank":null,"citation_count":27,"citer_count":27,"citers_with_citation_signal":19,"citers_with_endowment":19,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1662225,"name":"David Ramzy","orcid":null,"position":1,"is_corresponding":false},{"id":1662226,"name":"Ramy Ghaly","orcid":null,"position":2,"is_corresponding":false},{"id":176234,"name":"Raafat R. Abdel-Malek","orcid":null,"position":3,"is_corresponding":false},{"id":1662229,"name":"Kyrillus S. Shohdy","orcid":"0000-0001-8627-3605","position":4,"is_corresponding":false},{"id":1662224,"name":"Nafie F. Makady","orcid":"0000-0002-5036-9370","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"The Emerging Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient Outcomes","abstract":"Plasmablastic lymphoma (PBL) is a newly recognized aggressive subtype of non-Hodgkin lymphoma. Its rarity hinders testing effective treatment options in clinical trials. We conducted a systematic review of PubMed and our internal records to retrieve patients with a PBL diagnosis with evaluable treatment outcomes. Aggressive chemotherapy was defined as more intense regimens than CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone). We compiled a meta-dataset of 173 patients. The median age at diagnosis was 48.5 years, 75% of patients were male, and stages III/IV accounted for 47% of the cohort. Of 138 patients with known response status after first-line chemotherapy, 63 (45%) achieved a complete response with a 2-year relapse-free survival of 71.6%. Sixty-nine (50%) patients received first-line CHOP. There was no significant difference in the objective response rate among the 2 most commonly used regimens, CHOP and DA-EPOCH (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) (69% vs. 79%; P = .4). The median follow-up was 9 months, and the 2-year overall survival (OS) was 47.4%. A univariate analysis identified factors associated with worse OS, including stage III/IV (hazard ratio [HR], 2.82; P < .001), human herpes virus-8-positive (HR, 3.30; P = .01), bone marrow (HR, 1.07; P = .035), and cardiorespiratory involvement (HR, 2.26; P = .015). Meanwhile, Epstein-Varr virus-encoded small RNA-positivity (HR, 0.31; P < .001) and involvement of head and neck (HR, 0.44; P = .009) were associated with better OS. Multivariate analysis showed that aggressive chemotherapy was significantly associated with better OS (HR, 0.22; P = .016). Patients with PBL with high-risk features, such as advanced stage, human herpes virus-8-positivity, bone marrow, and cardiorespiratory involvement, require more aggressive chemotherapy. Bortezomib and lenalidomide are promising add-on agents.","is_dataset_classified":null,"base_score":3.332204510175204,"endowment":3.332204510175204,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"33419717","pmcid":null,"openalex_id":"https://openalex.org/W3108339790","authors":[],"funders":[{"funder_name":"Conquer Cancer Foundation","grant_id":"","title":null}],"total_grants":1,"fwci":1.1394,"citation_percentile":0.80881139,"influential_citations":0,"citation_trend":[{"year":2021,"count":2},{"year":2022,"count":6},{"year":2023,"count":7},{"year":2024,"count":6},{"year":2025,"count":6}],"oa_status":"closed","license":"https://doi.org/10.15223/policy-004","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S2152265020306674?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2152265020306674?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.clml.2020.11.025","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/33419717","host_type":"repository"}],"fields_of_study":["Viral-associated cancers and disorders","Lymphoma Diagnosis and Treatment","Chronic Lymphocytic Leukemia Research"],"mesh_terms":["Clinical Decision-Making","Plasmablastic Lymphoma","Antineoplastic Combined Chemotherapy Protocols","Disease Susceptibility","Humans","Prognosis","Comorbidity","Proportional Hazards Models","Treatment Outcome","Disease Management","Gene Expression Profiling","Kaplan-Meier Estimate"],"keywords":["Medicine","Plasmablastic lymphoma","Lymphoma","Oncology","Internal medicine","Intensive care medicine","Chemotherapy","Systematic review","Non-hodgkin Lymphoma","Proteasome inhibitors","Immunomodulatory Drugs"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T01:16:15.976517Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}